Registration and Continental Breakfast—Exhibits Open
Welcome and Opening Remarks, Giuliano Testa, MD, MBA, Baylor University Medical Center, and OptumHealth Education
Baylor Scott and White Health North Texas—Current Operating Environment, Gary Brock, President and Chief Operating Officer, Baylor Scott & White Health
(this session is not accredited)
Heart Transplantation: Past, Present, Future, Gonzalo V. Gonzalez-Stawinski, MD, Baylor University Medical Center
Heart transplantation continues to offer patients with end-stage heart failure a chance for a better quality and length of life. In recent years, the widening gap between the number of waiting recipients and the number of donors has resulted in a continuing trend toward transplanting urgent-status recipients and to a liberalization of donor acceptance criteria. This presentation will discuss donor criteria and the challenges faced by heart transplant centers to meet the demand.
- State the donor criteria for heart transplantation.
- Discuss the challenges faced by heart transplant centers.
- Identify strategies to sustain the growth of heart transplantation.
When to Refer: The Transplant Evaluation Process, Shelley Hall, MD, Baylor University Medical Center
Heart transplants are performed as a life-saving measure for end-stage heart failure when medical treatment and less drastic surgery have failed. Because donor hearts are in short supply, patients who need a heart transplant go through a careful selection process. This presentation will review the current heart failure guidelines and discuss the referral process for potential heart transplant candidates.
- Review new and current heart failure guidelines.
- Discuss management and treatment outcomes of patients with acute decompensated heart failure.
- Explain the referral process for potential heart transplant candidates.
Hub and Spoke System: The Extracorporeal Membrane Oxygenation (ECMO) Program, Omar Hernandez, BSN, RN, CCRN, Baylor University Medical Center
ECMO is used primarily in two ways: by providing rapid cardiac support for patients with acute heart failure, and also as a transitional “bridge” for patients awaiting heart surgery.This presentation will discuss the indication and utilization of ECMO for the acute-cardiac-failure patient awaiting transplant or placement of a ventricular assist device and the survival outcomes for this patient population.
- Recognize when ECMO therapy is indicated.
- Discuss utilization of ECMO for the acute-cardiac-failure patient awaiting transplant or placement of a ventricular assist device.
- State survival outcomes for patients placed in ECMO.
Left Ventricular Assist Device (LVAD): Present and Future, Brian Lima, MD, Baylor University Medical Center
Special considerations may be required for patients being managed long term with implantable LVADs. Because of the complexity of LVADs, managing these patients requires regular patient follow up, multidisciplinary care teams, and an understanding of complications that warrant close outpatient monitoring. This presentation will review the different types of LVADs and their clinical use in heart-failure patients, as well as discuss management strategies to reduce morbidity and mortality in heart-failure patients who are chronically supported with LVADs.
- List current devices for short-term treatment of heart failure.
- Identify long-term device strategies for heart-failure management.
- Explain the different types of LVADs and their clinical use in heart-failure patients.
Hope for the High-Risk Heart Transplant Patient, Gonzalo V. Gonzalez-Stawinski, MD, Baylor University Medical Center
Patients once considered too “high risk” for heart transplant may have renewed hope and another chance at being listed for transplant. This presentation will identify the high-risk patient and discuss the management of these complex patients and their available treatment options.
- Identify the high-risk heart transplant patient.
- State the management of the high-risk heart transplant patient.
- Discuss high-risk heart operations with circulatory support standby as an acceptable alternative to heart transplantation.
|12:00 p.m.||Heart Transplant Wrap-up, Gonzalo V. Gonzalez-Stawinski, MD, Baylor University Medical Center|
Lunch (provided)—Exhibits Open
Living Donor Liver Transplant: Why and When, Giuliano Testa, MD, MBA, Baylor University Medical Center
Living-donor transplant is a life-saving procedure for people with end-stage liver disease. It increases the number of available organs for people on the liver transplant waiting list and because the donor's liver is functioning up until the time of transplant, the recipient can benefit from improved long-term outcomes and a quicker recovery. This presentation will discuss the benefits of living donor transplants and what components are instrumental for a successful donor experience.
- Describe three benefits of living donor liver transplants.
- List four components of a flawless donor experience.
Managing the Wait List: The Balance Between Patient Wishes, Referring Physicians and Program Needs, Sumeet Asrani, MD, Baylor University Medical Center
Patients requiring a liver transplant are referred to a liver transplant center. After extensive evaluation, patients accepted for transplantation at each individual center are listed on the UNOS waiting list. During this time, challenges can occur in balancing the needs of patients, referring physicians and the transplant program.This presentation will discuss the composition of and access to the liver transplant waitlist, as well as the management of patients while they await allocation of a liver.
- Cite two examples of challenges that can occur in balancing the needs of patients, referring physicians and the transplant program.
- Describe the dynamics of wait-list criteria and potential for liver transplantation.
Preemptive Kidney Transplant: Avenue to Better Outcomes and Quality of Life, Bernard Fischbach, MD, Baylor Health Care System
Preemptive treatment uses transplantation as the primary renal replacement therapy in the absence of any preceding dialysis. This therapy maximizes the chance of maintaining a high quality of life and may avoid the morbidity of dialysis, as well as the associated financial costs. This presentation will describe the benefits of preemptive renal transplantation and the impact of dialysis on patient survival and quality of life.
- List three benefits of preemptive kidney transplantation.
- State the impact of dialysis on patient survival and quality of life.
The Finances of Transplantation: The Financial Impact of Living Donation, Kristin McClain, MBA, Baylor Annette C. and Harold C. Simmons Transplant Institute
Financing a transplant raises many questions and concerns for patients and their families. This presentation will discuss the advantages of creating separate cost centers for living donor and cadaveric donors and how limitations of coverage for donor complications impacts overall costs.
- List two reasons to support separating cost centers for living donors and cadaveric donors.
- Describe the impact of limitations of coverage for donor complications.
Total Pancreatectomy with Islet Auto Transplant, Marlon Levy, MD, Baylor All Saints Medical Center
Patients with chronic pancreatitis are generally referred for total pancreatectomy after other treatments have failed to adequately control their symptoms. Pancreatectomies with islet autotransplantation have promising results in terms of insulin independence and long-term islet graft function. This presentation will highlight the role of autologous islet cell transplantation in the treatment of chronic pancreatitis and how patient quality of life can be improved through autologous islet cell transplantation.
- Explain the role of autologous islet cell transplantation in the treatment of chronic pancreatitis.
- Describe how patient quality of life can be improved through autologous islet cell transplantation.
The Future of Kidney Transplant in the Era of an Aging Population, Increased Sensitization and Metabolic Disease, Bernard Fischbach, MD, Baylor Health Care System
With transplanted kidneys lasting an average of about 10 years, kidney transplant recipients are at increased risk of becoming sensitized to subsequent donor organs and metabolic disease. This presentation will discuss the impact of the patient’s age on kidney transplant outcomes and describe the role of desensitization therapy.
- Describe the role of desensitization therapy in kidney transplantation.
- Review the impact of the patient’s age on kidney transplant outcomes.
|4:30 p.m.||Adjourn, Giuliano Testa, MD, MBA, Baylor University Medical Center|
Complimentary Get-Acquainted Reception—Exhibits Open
Please join us for complimentary drinks and hors d’oeuvres. This unique evening will provide attendees the opportunity to get further acquainted with staff members from Baylor Health Care System.